Facebook Instagram Pinterest Reddit Tumblr X Youtube

Home
About
News
Events
Shop
Directory
Contact Us

Search

Sign in

Welcome! Log into your account

your username

your password

Forgot your password? Get help

Password recovery

Recover your password

your email

A password will be e-mailed to you.

Home
About
News
Events
Shop
Directory
Contact Us

The Psychedelic News Feed: March 4, 2024 – September 1, 2024

By

-

September 23, 2024

19

Previous articlePα+ Psychedelic Bulletin #173: Upcoming Trial Readouts to Watch; Lykos Prioritises Preparing for Resubmission Over Formal Dispute

Next articleIntention, Making Space for Integration, and Finding Joy in the Mundane

https://psynews.com

RELATED ARTICLES MORE FROM AUTHOR

Pα+ Psychedelic Bulletin #227: A Closer Look at Compass’ 6-Month Data; AtaiBeckley Deal Update; ‘Rysanso’ Brand MDMA?

Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch

Psychedelic Policy Briefing: Week of July 6, 2026

Newsletter

EDITOR PICKS

Pα+ Psychedelic Bulletin #227: A Closer Look at Compass’ 6-Month Data;...

Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27...

Psychedelic Policy Briefing: Week of July 6, 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

FOLLOW US

Facebook Instagram Pinterest Reddit Tumblr X Youtube

©

MORE STORIES

Pα+ Psychedelic Bulletin #227: A Closer Look at Compass’ 6-Month Data;...